Stockreport

CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF The recent NVO CagriSema trial failed to close the efficacy gap with LLY's Zepbound, intensifying competitive pressure on NVO. Novo's impressive uptake of oral Wegovy [Read more]